NCT02727777View on ClinicalTrials.gov

Phase II Study of TAK228 in Relapsed Lymphoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

July 10, 2018

Study Completion Date

July 10, 2018

Conditions
Lymphoma
Interventions
DRUG

TAK228

Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.

OTHER

Blood Sugar Testing

Participant given a glucometer to check pre-dose blood sugar levels at home every day.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER